alcmi.bsky.social - Profile | ThreadSky | a Reddit-style client for Bluesky

New data from the KRYSTAL-7 trial showed encouraging results for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). Adagrasib plus pembrolizumab—without chemotherapy—showed promising survival benefits. #lungcancer www.cancernetwork.com/view/adagras...

submitted 11 hours ago • 0 comments

In her interview with pharmaphorum, Biljana Naumovic, President of Solid Tumor for US Oncology at J&J, emphasized a critical shift that clinicians need to understand: it's not just about treating the disease. #lungcancer pharmaphorum.com/oncology/lif...

submitted 1 day ago • 0 comments

Big news! The FDA just granted priority review to Bayer’s sevabertinib for HER2-positive non-small cell lung cancer. #lungcancer www.oncnursingnews.com/view/sevaber...

submitted 2 days ago • 0 comments

A new study from MD Anderson Cancer Center, published in Nature Medicine, has identified TTF-1 as a biomarker that could determine which patients will benefit most from sotorasib, the first FDA-approved KRAS inhibitor. #lungcancer www.mdanderson.org/newsroom/new...

submitted 3 days ago • 0 comments

Congratulations to Narjust Florez M.D. FASCO and all our friends at Dana-Farber Cancer Institute for the launch of the new EQUAL trial! #lungcancer www.dana-farber.org/newsroom/new...

submitted 4 days ago • 0 comments

New research at Memorial Sloan Kettering Cancer Center expands our understanding of metastasis in small cell lung cancer! #lungcancer www.nature.com/articles/s41...

submitted 5 days ago • 0 comments

New clinical trial data reveal that combining Roche’s immunotherapy Tecentriq with Jazz Pharmaceuticals's Zepzelca as maintenance therapy extended survival for patients with small cell lung cancer. #lungcancer www.biopharmadive.com/news/zepzelc...

submitted 6 days ago • 0 comments

Researchers at the Cleveland Clinic Cancer Institute, the University of Cambridge, and the University of Minnesota have just secured a $1M grant. #lungcancer consultqd.clevelandclinic.org/novel-partne...

submitted 7 days ago • 0 comments

Big news in the fight against small cell lung cancer! Zai Lab's ZL-1310 just earned FDA fast-track designation. #lungcancer www.curetoday.com/view/fda-gra...

submitted 8 days ago • 0 comments

Cancer Network reports that new 5-year data from the phase 3 CROWN trial may shift the standard of care in ALK-positive NSCLC. #lungcancer www.cancernetwork.com/view/explori...

submitted 9 days ago • 0 comments

Congratulations to our friends at AbbVie! Roche’s VENTANA MET (SP44) RxDx Assay is now officially cleared to identify patients with high MET protein expression, opening the door for treatment with AbbVie’s targeted therapy, Emrelis. #lungcancer pharmafile.com/news/fda-app...

submitted 10 days ago • 0 comments

What if a single low-dose CT scan could tell you with remarkable accuracy whether you’re at risk for lung cancer, even if you’ve never smoked? #lungcancer www.insideprecisionmedicine.com/topics/oncol...

submitted 11 days ago • 0 comments

At the recent CURE Educated Patient Lung Cancer Summit, Dr. Arthi Sridhar from UT Southwestern Medical Center highlighted that younger patients with lung cancer are significantly more likely to have targetable mutations. #lungcancer www.curetoday.com/view/younger...

submitted 12 days ago • 0 comments

Merck has announced the presentation of significant new research findings from its oncology portfolio and pipeline at the upcoming ASCO 2025 Annual Meeting, May 30–June 3. #lungcancer www.merck.com/news/researc...

submitted 13 days ago • 0 comments

At the upcoming 26th Annual International Lung Cancer Congress, researchers are preparing to discuss what happens next when resistance emerges in EGFR-mutated NSCLC. #lungcancer www.targetedonc.com/view/experts...

submitted 14 days ago • 0 comments

For those tracking innovation in lung cancer treatment, this recap from Calley Jones, Ph.D., for the American Association for Cancer Research blog is worth your time. #lungcancer www.aacr.org/blog/2025/05...

submitted 15 days ago • 0 comments

An exploratory subgroup analysis of the EMPOWER-Lung 1 trial, published in Cancer, reveals some promising findings for first-line cemiplimab (Libtayo) in patients with advanced NSCLC, brain metastases, and high PD-L1 expression. #lungcancer www.onclive.com/view/cemipli...

submitted 16 days ago • 0 comments

PLK4 inhibition is emerging as a compelling strategy to enhance the impact of radiation in non–small cell lung cancer. #lungcancer aacrjournals.org/mct/article-...

submitted 17 days ago • 0 comments

The FDA just granted accelerated approval to AbbVie's Emrelis (telisotuzumab vedotin), a first-in-class treatment for a specific subset of non-small cell lung cancer patients. #lungcancer www.medpagetoday.com/hematologyon...

submitted 18 days ago • 0 comments

Don’t miss this 🎧: Our board & medical committee member Marc Muskavitch, PhD joins UpStage Lung Cancer’s podcast for a powerful convo on ALK+ #lungcancer. Why early detection & #BiomarkerTesting are critical to improving outcomes. #lcsm 🦻upstagelungcancer.org/podcasts/livin…

submitted 20 days ago • 0 comments

If you’re interested in where #lungcancer vaccines are at relative to #melanoma, check out this @togaanz.bsky.social podcast with @gvlongphdmd.bsky.social and Ken OByrne. podcasts.apple.com/au/podcast/v... open.spotify.com/episode/0OJb...

submitted 19 days ago • 0 comments

Biomark Diagnostics Inc. just reached a major milestone, validating the high accuracy of its liquid biopsy test for early-stage lung cancer detection. #lungcancer www.biospace.com/press-releas...

submitted 19 days ago • 0 comments

At #ELCC2025, final survival results from the phase III MARIPOSA trial showed that patients with EGFR-mutated non–small cell lung cancer lived significantly longer when treated with amivantamab-vmjw plus lazertinib compared to osimertinib. #lungcancer ascopost.com/issues/may-1...

submitted 20 days ago • 0 comments

Proud to share a new article from ALCMI's COO and Executive Director, Richard Erwin, shedding light on the urgent need for innovation, collaboration, and bold action in the fight against small cell lung cancer. #lungcancer alcmi.org/media-resour...

submitted 21 days ago • 0 comments

For patients with advanced non-small cell lung cancer who haven’t responded to immune checkpoint inhibitors, CAN-2409 plus valacyclovir is showing remarkable promise. #lungcancer www.healio.com/news/hematol...

submitted 22 days ago • 0 comments

iOctura recently launched a randomized Phase I/II study investigating whether roginolisib, combined with dostarlimab, can help reprogram the immune system to prevent or reverse resistance in non-small cell lung cancer. #lungcancer www.prnewswire.com/news-release...

submitted 23 days ago • 0 comments

A new study from the Fred Hutchinson Cancer Research Center, published in Science Advances, takes a look at why small cell lung cancer can respond so dramatically to chemotherapy, only to relapse just as quickly. #lungcancer www.fredhutch.org/en/news/cent...

submitted 24 days ago • 0 comments

At ALCMI's consortium member, Montefiore Einstein Comprehensive Cancer Center, Dr. Nitin Ohri and his team are advancing NSCLC treatment options with the phase 2 SPRINT trial. #lungcancer www.onclive.com/view/persona...

submitted 25 days ago • 0 comments

Suppressing APOBEC enzymes—key drivers of tumor mutations—could dramatically delay drug resistance in non-small cell #lungcancer (#NSCLC), up to 1200%! Targeting the generation of variation may be the best route to personalized and durable treatments 🧪. ysph.yale.edu/news-article... #Medsky

submitted 28 days ago • 1 comment

In a recent interview with OncLive, Dr. Alexis Chidi of Memorial Sloan Kettering Cancer Center explained how the gold standard of lung cancer surgery—removing an entire lobe of the lung (a lobectomy)—is giving way to less invasive options. #lungcancer www.onclive.com/view/less-is...

submitted 26 days ago • 0 comments

Wow, new research presented at hashtag#ESTRO2025 introduces the RAPID-RT study from The Christie NHS Foundation Trust, a significant advancement in lung cancer radiotherapy evaluation. #lungcancer www.news-medical.net/news/2025050...

submitted 27 days ago • 0 comments

New research led by Dr. Teja Voruganti and published in the American Society of Clinical Oncology (ASCO) Educational Book dives deep into perioperative lung cancer therapy strategies—what’s working, what’s promising, and what’s still unclear. #lungcancer ascopubs.org/doi/10.1200/...

submitted 28 days ago • 0 comments

A new study from Yale School of Public Health, led by Dr. Jeffrey Townsend, offers an interesting strategy to slow cancer down by targeting the very process that helps it outsmart our best therapies. #lungcancer medicalxpress.com/news/2025-05...

submitted 29 days ago • 0 comments

A new study published in Nature Magazine's Experimental & Molecular Medicine explores how cannabidiol (CBD)—better known for managing epilepsy—can dramatically enhance the cancer-fighting potential of etoposide in non-small cell lung cancer. #lungcancer www.nature.com/articles/s12...

submitted 30 days ago • 0 comments

Phase 2 KEYLYNK-007 trial findings suggest a new avenue through the combination of olaparib and pembrolizumab in previously treated solid tumors harboring homologous recombination repair mutations and/or homologous recombination deficiency. #lungcancer www.oncologynewscentral.com/oncology/tum...

submitted 31 days ago • 0 comments

Dr. Yuanyuan Zhang and researchers at UT Southwestern Medical Center have found that devimistat—an FDA-designated orphan drug—may supercharge the impact of radiation therapy. #lungcancer www.utsouthwestern.edu/newsroom/art...

submitted 32 days ago • 0 comments

Fascinating and concerning study out of Memorial Sloan Kettering Cancer Center. Dr. Jung Hun Oh and colleagues discovered that lung cancer can hijack genes normally crucial for fetal development and immune evasion during pregnancy. #lungcancer www.mskcc.org/news/pregnan...

submitted 33 days ago • 0 comments

If we want to beat lung cancer, we need better models. Mouse models have been essential for research, but they’re fragmented, and silos make it hard to compare results across studies. #lungcancer aacrjournals.org/cancerres/ar...

submitted 34 days ago • 0 comments

This week, The New England Journal of Medicine published a new study on Boehringer Ingelheim's zongertinib that could be a game changer. #lungcancer www.nejm.org/doi/full/10....

submitted 35 days ago • 0 comments

For years, the KRAS gene mutation in cancer was considered "undruggable," impacting so many, particularly in lung, pancreatic, and colorectal cancers. Then came the first breakthrough for one subtype. #lungcancer www.mskcc.org/news/potenti...

submitted 36 days ago • 0 comments

At the American Association for Cancer Research Annual Meeting, researchers shared early but exciting news about zoldonrasib, an experimental drug targeting the KRAS G12D mutation in non-small cell lung cancer. #lungcancer www.moffitt.org/endeavor/arc...

submitted 37 days ago • 0 comments

Congratulations to Raymond Chalmé, Dr. Joan Schiller, and AstraZeneca! Each will be honored at the Lung Cancer Research Foundation's 2025 Evening of Innovation gala. #lungcancer www.prnewswire.com/news-release...

submitted 38 days ago • 0 comments

The EU has approved Tumor Treating Fields (TTFields) combined with immunotherapy or docetaxel in metastatic NSCLC after progression. The phase 3 LUNAR trial demonstrated a significant overall survival benefit. #lungcancer www.cancernetwork.com/view/ttfield...

submitted 39 days ago • 0 comments

Wow, "remarkable change" doesn't even begin to cover it when we're talking about the evolution of care for EGFR-mutated non-small cell lung cancer. Dr. Shirish Gadgeel and Dr. Robert Figlin discuss. #lungcancer www.oncologynewscentral.com/podcast/how-...

submitted 40 days ago • 0 comments

Phase 3 data published in The Lancet Respiratory Medicine show that high-dose, twice-daily thoracic radiotherapy paired with concurrent chemotherapy holds that promise for patients battling limited-stage SCLC. #lungcancer www.cancernetwork.com/view/high-do...

submitted 41 days ago • 0 comments

A new study in AACR Journals' Clinical Cancer Research by Dana-Farber Cancer Institute's Dr. Federica Pecci and colleagues looks at immune checkpoint inhibitors and what happens when these therapies are cut short due to immune-related adverse events. #lungcancer aacrjournals.org/clincancerre...

submitted 42 days ago • 0 comments

Researchers at Stanford University School of Medicine have developed RARE-seq, an ultrasensitive method for detecting cell-free RNA (cfRNA) in blood plasma, and the implications for cancer detection and monitoring are enormous. #lungcancer www.nature.com/articles/s41...

submitted 43 days ago • 0 comments

Only 18% of eligible patients in the U.S. get screened for lung cancer. Our consortium member, City of Hope, explored the reasons in a recent article. #lungcancer www.cityofhope.org/hope-matters...

submitted 44 days ago • 0 comments

Amgen's Phase III DeLLphi-304 trial found that Imdelltra (tarlatamab-dlle) delivered a statistically significant improvement in overall survival for patients with SCLC that had progressed following platinum-based chemotherapy. #lungcancer www.pharmexec.com/view/amgen-i...

submitted 45 days ago • 0 comments

The treatment landscape for EGFR-positive non-small cell lung cancer (NSCLC) is changing, and pharmacists are becoming key decision-makers in navigating that complexity. #lungcancer www.pharmacytimes.com/view/more-op...

submitted 46 days ago • 0 comments